FDA approves Novartis, Momenta's MS drug

The U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceutical's blockbuster multiple-sclerosis drug Copaxone, although it remains unclear when the copycat version may come to market. The generic, known as Glatopa, was developed by Novartis AG's Sandoz business and Momenta Pharmaceuticals Inc. Sandoz is evaluating the timing of the launch, Momenta said in a news release.

http://ift.tt/1PU62w4